PubMed Health⌕ Search

Biomedical subjects

A Depierre

Publications and source records attributed to A Depierre.

10 recordsLinked to original sources
PubMed1979

Phase I trial with peptichemio.

Thirty-two patients with tumor progression, even after conventional cytostatic drug treatment, were treated with peptichemio, with increasing doses for groups of 4 patients. The maximum tolerated dose (with minimum hematological toxicity and without any other evident toxicity) with repeated administrations, was 1.2 mg/kg twice weekly. The recommended doses for phase II trials are, as shown by the detailed analysis of the results, 0.9 mg/kg, twice weekly and administered alone, and 1.3 mg/kg, once weekly combined with other cytostatic drugs, in 500 ml of infusion fluid, with 25 mg of heparin and 25 mg of hydrocortisone to minimize the freqent risk of local phlebosclerosis.

Adult↗
PubMed1979

[Preliminary results of postoperative trial therapy of epidermoid cancer of the lung (European Organization for Research on the Treatment of Cancer, Bronchus Group. Protocol 08741)].

650 patients entered the study between 5/74 and 4/79 and are currently evaluable. Prior to entry, all underwent complete resection of squamous cell bronchial carcinoma. Patients were initially randomized to receive radiotherapy versus no radiotherapy. Following that a second stage randomization ascribed patients to chemotherapy, immunotherapy, immunochemotherapy and observation. Current analysis of results shows that : 1. Patients with negative nodes did not benefit from post-operative radiotherapy; on such patients, survival was significantly shorter following radiotherapy. 2. In patients with positive nodes, post-operative radiotherapy prevented local recurrence, but did not prolong survival. The data from the second stage randomization are currently being analyzed.

Bronchial Neoplasms↗
PubMed1978

[Comparative study of carcino-embryonic antigen and beta2-microglobulin. Methodological study and clinical interpretation (author's transl)].

beta2m was determined by radioimmunoassay in 43 serums from healthy blood donors. Serum concentrations varied from 0.67 to 1.9 mg/l with a mean of 1.29 mg/l. Reproductibility and sensitivity of the method were evaluated. 66 patients with advanced neoplasia were studied. Serum beta2m was greater than 2 mg/l in 70% of the cases and carcinoembryonic antigen (CEA) in 54%. In 26 documented cases with tumor progression and 14 with regression, associated variations of CEA were formed more frequent and of greater magnitude than those of beta2m.

Beta-Globulins↗
PubMedDate not supplied

[Long survival periods after therapy for metastatic or reccurrent cancer (author's transl)].

Out of 671 cases of various cancers, first seen for growing metastases and or recurrences (resectable cases being excluded) the 3 years survival rate has been 18 per cent (121 cases). This result was obtained by various combinations of chemotherapy and radiotherapy. It follows that advanced cases should not be abandoned without any attempt at control, and that earlier treatments in cases being at high risk for metastases would probably further increase such results.

Adenocarcinoma↗
PubMedDate not supplied

Immunochemotherapy in 34 cases of oat cell carcinoma of the lung with 19 complete responses.

Thirty-four previously untreated patients with oat cell carcinoma of the lung were treated with a myelotoxic combination of cyclophosphamide, adriamycin, methotrexate, CCNU, and Corynebacterium parvum (regimen A) every 4 weeks, interspersed with a non-myelotoxic combination including bleomycin, vincristine, dehydroemetine, and Corynebacterium parvum (regimen B) weekly the other 3 weeks or when hematologic toxicity prohibited administration of regimen A. Hematologic toxicity was frequent but was never a serious problem except in two cases of profound leukopenia in which fatal supervening infection occurred. Nineteen patients in this series (56%) showed a complete response lasting from 4+ to 65+ months. Eight of these patients are still alive with a followup of 6+ to 65+ months. Nine patients (26%) showed a partial response (greater than 50%) lasting 1-10+ months. Only one patient in this group is surviving (10+ months). The overall response rate was thus 82%. It is concluded from this study that only a complete response has any significant effect on survival, the benefit of a partial response over no response being only slight. The results achieved are compared to those of available series in the literature and from this comparison strategic deductions for the treatment of oat cell carcinoma of the lung are made.

Adult↗